Backs FY26 revenue view $1.23B-$1.25B, consensus $1.24B. Backs FY26 adjusted EBITDA view $632M-$641M. The company said, “The outlook provided above contains a number of assumptions, including, among others, the Company’s current expectations regarding supply chain continuity, particularly for the supply of ethylene oxide and Cobalt-60, and the impact of inflationary trends including their impact on energy prices and the supply of labor.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health Names New CEO, Highlights Leadership Transition
- Sotera Health price target lowered to $18 from $20 at Barclays
- Sotera Health Adds Independent Director Amid Board Reshuffle
- Sotera Health appoints Kenneth Krause to board of directors
- Sotera Health Completes Large Secondary Shareholder Stock Sale